SUPPLEMENTARY MATERIAL

Biomarker Changes Associated with both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control *post hoc* Analysis

Contents

		Page
Supplemental	Description of Metabolite Assay Methods	2
Table S1:	List of Measured Proteins and the Assay Systems Used for Analyses	3
Table S2:	Coefficient of Variance (CV) and Lower Limit of Detection of Protein	4
	Biomarker Assays	
Table S3:	List of Metabolite Biomarkers in the Analysis	5
Table S4:	Adjusted Effect of Dulaglutide on the 2-Year Change in Protein Levels	7
Table S5:	Sensitivity Analysis: Association Between MACE Status and Change in Specific	:
	Biomarker Levels from Baseline, After Excluding Cases that Occurred Before	
	the 2-Year Visit (and their Controls)	8
Table S6:	Adjusted Effect of Dulaglutide on the 2-Year Change in Metabolite Levels	9

Supplemental Description of Metabolite Assay Methods

Targeted metabolomics was performed on plasma samples collected after 2 years from patient enrollment. Plasma samples were frozen immediately after collection and thawed prior to analysis. Metabolomics data were acquired using a targeted liquid chromatography-mass spectrometry approach. Data were acquired using a Shimadzu Nexera X2 UHPLC system coupled to an AB SCIEX 6500+ triple quadrupole mass spectrometer equipped with an electrospray source. Two chromatographic methods were applied: one using a Waters Acquity BEH Amide 15 mm \times 2.1 mm, 3.5 µm particle size, column (assay A), and another using a Waters XSelect HSS T3 C18 15 mm × 2.1 mm, 3.5 µm particle size, column (assay B). Both columns were maintained at $+40^{\circ}$ C. Elution solvents for both methods were 10 mM ammonium formate adjusted with 0.1% formic acid (solvent A) and 0.1% formic acid in acetonitrile (solvent B) and run under gradient conditions. Data were acquired using scheduled multiple reaction monitoring (MRM) mode with polarity switching. A total of 250 polar metabolites were targeted. For most of the metabolites, identification was supported by one qualifier ion monitored in addition to a quantifier ion. To resolve interferences amongst specific metabolites, two qualifier ions were monitored (data not reported). Two extraction protocols were used for assay A and B, respectively. Frozen plasma samples were thawed in an ice bath. For assay A, 150 µL of prechilled acetonitrile-methanol (1:1 v/v) solvent mixture was added to $25-\mu$ L plasma aliquot. For assay B, 150 μ L of pre-chilled methanol-water (4:1 v/v) solvent mixture was added to a second 25- μ L plasma aliquot. Samples were mixed thoroughly and incubated at -20°C overnight. Both extraction solutions were spiked with a mix of stable labeled internal standards. The samples were then centrifuged for 15 min at 14000 g at $+4^{\circ}$ C, and the supernatants were removed for LC-MS/MS analysis. For each assay, a pooled calibrator sample was created for each method by combining an aliquot of the same volume from all the extracted samples together. The pooled calibrator (100% calibration point) was serially diluted in the same extraction solvent and used to create a calibration curve (75%, 60%, 40%, 25%, 10%) for relative quantitation and batch-tobatch data normalization. A pooled QC sample was also prepared at 50% (1:1 v/v dilution). Individual samples were further diluted 1:1 (v/v) with extraction solution, transferred into a 96well plate and injected for LC-MS/MS analysis. Only analytes detected at the lowest pooled calibrator with signal-to-noise > 3 and detected in more than 75% of the individual samples were quantified. Relative quantitation to the pooled calibrators was achieved using a log-log linear regression model. Relative values extrapolated outside the calibration curve were not imputed. Peak areas were integrated using the AB SCIEX MultiQuant 3.0.2 software. Metabolite areas were normalized to matched internal standard area responses. For analytes with no matching stable labeled internal standards, the optimal match (picked amongst the internal standards monitored under the same polarity and within the same assay) was the one giving the minimum relative standard deviation of the pooled calibrator responses and best linearity fit. For statistical analysis metabolites showing coefficient of variations (CV%) below 20% for the qualifier-toquantifier MRM ratio, as well as linear regression coefficients (R2) above 0.85 were reported.

Table S1: List of Measured Proteins and the Assay Systems Used for Analyses		
Protein Biomarker	Assay System	
High sensitivity C-reactive Protein	Roche Cobas	
Growth Differentiation Factor 15	R&D Systems ELISA	
C-Peptide	Roche Cobas	
NT-proBNP	MSD V-plex	
Intact Proinsulin	Invitron ELISA	
Insulin like growth factor binding protein 2	R&D Systems ELISA	
Serum amyloid A	MSD V-plex Vascular Inflammation panel	
Apolipoprotein B	Roche Cobas	
Apolipoprotein CIII	Roche Cobas	
Interleukin 6	MSD V-plex proinflammatory panel	
Cytokeratin 18	Diapharma ELISA	
Interferon gamma	MSD V-plex proinflammatory panel	
Soluble intercellular adhesion molecule 1	MSD V-plex Vascular Inflammation panel	
Soluble vascular cell adhesion molecule 1	MSD V-plex Vascular Inflammation panel	
Interleukin 8	MSD V-plex proinflammatory panel	
Interleukin 10	MSD V-plex proinflammatory panel	
Apolipoprotein Al	Roche Cobas	
Insulin	In house ELISA	
Tumor necrosis factor alpha	MSD V-plex proinflammatory panel	

Protein Biomarker	Lower Limit of	Intra-assay	Inter-assay %CV
	Detection	%CV	
High sensitivity C-reactive Protein	0.15 mg/L	single sample	<3 SD of Roche clinical-
		analysis	grade quality control
Growth Differentiation Factor 15	8.95 pg/mL	2.7%	10.4%
C-Peptide	0.01 ng/mL	single sample	<3 SD of Roche clinical-
		analysis	grade quality control
NT-proBNP	1.52 pg/mL	6.0%	6.4%
Intact Proinsulin	3.6 pmol/L	18%	13%
Insulin like growth factor binding protein 2	14.3 ng/mL	8.0%	5.9%
Serum amyloid A	0.97 ng/mL	6.1%	11.3%
Apolipoprotein B	3 mg/dL	single sample	<3 SD of Roche clinical-
		analysis	grade quality control
Apolipoprotein CIII	3 mg/dL	single sample	<3 SD of Roche clinical-
		analysis	grade quality control
Cytokeratin 18	65.1 U/L	11.6%	13%
Interferon gamma	0.06 pg/mL	3.7%	3.6%
Interleukin 6	0.005 pg/mL	4.6%	5.9%
Soluble intercellular adhesion molecule 1	0.15 ng/mL	5.9%	5.3%
Soluble vascular cell adhesion molecule 1	0.65 ng/mL	4%	2.1%
Interleukin 8	0.01 pg/mL	4.5%	7.8%
Interleukin 10	0.01 pg/mL	9.96%	10.1%
Apolipoprotein Al	3 mg/dL	single sample	<3 SD of Roche clinical-
	-	analysis	grade quality control
Insulin	6.1 pg/mL	6.3%	8.9%
Tumor necrosis factor alpha	0.05 pg/mL	4.2%	6.3%

Table S2: Coefficient of Variance (CV) and Lower Limit of Detection of Protein Biomarker Assays

SD – standard deviation

Table S3: List of Metabolite Biomarkers in the Analysis

Arginine

2-hydroxybutyric acid Threonine 3-hydroxybutyric acid Asparagine Guanidinoacetic acid Citrulline Free carnitine Hydroxydecanoylcarnitine Glutamine Creatine Uridine monophosphate Glycine 3-hydroxyisobutyric acid 3-phenyllactic acid CMPF^1 2-hydroxy-3-methylbutiric acid Hydroxydodecenoylcarnitine Tyrosine **Butenoylcarnitine** Dodecenoylcarnitine Ketoleucine Alpha-ketoisovaleric acid Asymmetric dimethylarginine Uridine Leucine Decenoylcarnitine Ornithine tetradecadienoylcarnitine 2-aminobutyric acid Eicoseneoylcarnitine Lactic acid Trimethylamine-N-oxide N –alpha acetyl-L-arginine Hydroxyproline Cholesterol sulfate Pyroglutamic acid N-2-furoylglycine N-acetylglutamic acid Imidazole-4-acetic acid Cystine Valine

Octanoylcarnitine Hydroxytetradecenoylcarnitine Octenoylcarnitine Tetradecenoylcarnitine N-acetylthreonine Tryptophan Creatinine Acetylcarnitine Serine Palmitoleoylcarnitine Nicotinamide N-acetylmethionine Octadecanoylcarnitine Linoleoylcarnitine Xanthurenic acid Decanoylcarnitine 1-methyladenosine Decatrienoylcarnitine Arachidoylcarnitine Urea Succinic acid N-alpha-acetyllysine Palmityolcarnitine 3-aminoisobutyric acid Heptanoylcarnitine Methionine sulfoxide Betaine Myristoylcarnitine N-acetylputrescine 3-methyl-2-oxovaleric acid 1-methylnicotinamide N, N-dimethylglycine Butyrylcarnitine 4-pyridoxic acid Phenylalanine 2-hydroxyisocaproic acid C18:3 carnitine Xanthine Mevalonic acid Kynurenic acid

Beta-alanine Hydroxyoctenoylcarnitine Arachidonoylcarnitine N-acetylaspartic acid Isoleucine Malic acid Glutaric acid Proline Phenylpyruvic acid Kynurenine Allantoin Decadiencylcarnitine 2,3-pyridinedicarboxylic acid Taurine N-acetylserine Lysine Sarcosine S-adenosylhomocysteine Glutamic acid N-acetyltryptophan N-acetylalanine 2-aminoadipic acid Pantothenic acid Citric acid Uric acid Isovalerylcarnitine Hypoxanthine Trans aconitic acid C6:2 carnitine Riboflavin Propionylcarnitine Aspartic acid Symmetric dimethylarginine Inosine Alanine 1-methylhistidine S-methylcysteine sulfoxide Isocitric acid Alpha-ketoglutaric acid 3-methylhistidine Histidine

Oleoylcarnitine	4-oxoproline_pipecolicacid	Guanosine
Hexadecadienoylcarnitine	N-epsilon-acetyllysine	Ethanolamine
N-acetylcitrulline	2,3-dihydroxybenzoic acid	S-methylcysteine
Homocitrulline	Dodecanoylcarnitine	N-acetylornithine
1		

¹CMPF - carboxy-4-methyl-5-propyl-2-furanpropanoic acid

Table 54: Association of Dulagiutide with the 2-Year Change in Protein Levels			
Protein Biomarker	Beta Estimate (95%CI) for Dulaglutide	P*	
High sensitivity C-reactive Protein	-0.203 (-0.297, -0.110)	0.000020*	
Growth Differentiation Factor 15	-0.079 (-0.112, -0.045)	0.000006*	
C-Peptide	0.135 (0.070, 0.200)	0.000050*	
NT-proBNP	-0.145 (-0.229, -0.060)	0.000845*	
Intact Proinsulin	-0.094 (-0.156, -0.031)	0.003511	
Insulin like growth factor binding protein 2	0.049 (0.014, 0.084)	0.005720	
Serum amyloid A	-0.131 (-0.236, -0.026)	0.014509	
Apolipoprotein B	-0.022 (-0.043, 0.000)	0.051646	
Apolipoprotein CIII	-0.047 (-0.100, 0.006)	0.083511	
Cytokeratin 18	-0.046 (-0.100, 0.009)	0.103077	
Interferon gamma	0.017 (-0.058, 0.093)	0.169657	
Interleukin 6	-0.039 (-0.100, 0.022)	0.211904	
Soluble intercellular adhesion molecule 1	-0.024 (-0.064, 0.015)	0.231563	
Soluble vascular cell adhesion molecule 1	-0.024 (-0.065, 0.016)	0.231781	
Interleukin 8	0.038 (-0.025, 0.101)	0.239601	
Interleukin 10	0.036 (-0.032, 0.103)	0.304340	
Apolipoprotein Al	0.003 (-0.009, 0.015)	0.576137	
Insulin	-0.014 (-0.078, 0.050)	0.662862	
Tumor necrosis factor alpha	-0.004 (-0.040, 0.032)	0.836807	

 Table S4: Association of Dulaglutide with the 2-Year Change in Protein Levels

The effect of dulaglutide on the 2-year difference of the natural logarithm (In) levels of each protein (calculated as In (2-year/baseline) adjusted for In (baseline biomarker level), age, sex, white identification, systolic blood pressure, previous cardiovascular disease, current smoking, body mass index, HbA1c, eGFR, LDL cholesterol, and albuminuria is shown. The biomarkers are sorted from the lowest to highest P values for the beta coefficient, and negative values denote a greater fall in level from baseline to 2 years with dulaglutide versus placebo. *P values that are significant at a level of 0.05/19 = 0.0026.

		Adjusted for Dulaglutide and Risk Factors OR per Unit Higher Level (95%CI)	Р
Proteins	High sensitivity CRP	1.207 (1.069, 1.362)	0.002
	NT-proBNP	1.128 (0.980, 1.297)	0.094
	GDF15	1.709 (1.208, 2.418)	0.002
	C-peptide	1.162 (0.984, 1.371)	0.076
Metabolites	2-hydroxybutyric Acid	1.146 (0.812, 1.619)	0.439
	Threonine	1.018 (0.511, 2.026)	0.960

 Table S5: Sensitivity Analysis: Association Between MACE Status and Change in Specific Biomarker

 Levels from Baseline, After Excluding Cases that Occurred Before the 2-Year Visit (and their Controls)

OR – odds ratio; CI – confidence interval; The relationship between a 1-unit higher Ln(2-year) – Ln (baseline) is shown. Risk factors included in the model were age, sex, white self-identification, systolic blood pressure, previous cardiovascular disease, current smoking, body mass index, HbA1c, the estimated glomerular filtration rate (eGFR), LDL cholesterol, and albuminuria and (for the dulaglutide model) and the interaction of dulaglutide and the change in biomarker. The significance threshold for proteins is 0.05/4=0.0125.

Table S6: Association of Dulaglutide with the 2-Year Change in Metabolite Levels			
Metabolite Biomarker	Beta Estimate (95%CI) for Dulaglutide	Р*	
2-hydroxybutyric acid	-0.100 (-0.148, -0.053)	0.000041*	
Threonine	0.044 (0.021, 0.068)	0.000266*	
8-hydroxybutyric acid	-0.150 (-0.237, -0.063)	0.000769	
Asparagine	0.030 (0.012, 0.047)	0.000796	
Guanidinoacetic acid	0.054 (0.021, 0.087)	0.001581	
Citrulline	0.070 (0.026, 0.115)	0.001892	
ree carnitine	0.033 (0.012, 0.054)	0.002175	
lydroxydecanoylcarnitine	-0.070 (-0.118, -0.023)	0.003709	
Glutamine	0.023 (0.006, 0.039)	0.006757	
Creatine	0.057 (0.016, 0.099)	0.006885	
Jridine monophosphate	0.027 (0.007, 0.048)	0.01014	
Slycine	0.033 (0.007, 0.058)	0.011068	
8-hydroxyisobutyric acid	-0.049 (-0.086, -0.011)	0.011594	
8-phenyllactic acid	0.061 (0.014, 0.109)	0.011765	
	-0.137 (-0.245,-0.03)	0.012445	
2-hydroxy-3-methylbutiric acid	-0.058 (-0.105, -0.011)	0.015344	
lydroxydodecenoylcarnitine	-0.075 (-0.137, -0.013)	0.017916	
- yrosine	0.024 (0.004, 0.045)	0.020921	
Butenoylcarnitine	-0.055 (-0.102, -0.008)	0.022623	
Dodecenoylcarnitine	-0.059 (-0.11, -0.007)	0.025315	
Ketoleucine	-0.03 (-0.057, -0.003)	0.02826	
Alpha-ketoisovaleric acid	-0.03 (-0.056, -0.003)	0.028751	
Asymmetric dimethylarginine	0.018 (0.002, 0.035)	0.030252	
Jridine	-0.035 (-0.068, -0.003)	0.034513	
eucine	-0.023 (-0.046, -0.001	0.041282	
Decenoylcarnitine	-0.046 (-0.09, -0.002)	0.041838	
Drnithine	0.037 (0.001, 0.072)	0.04386	
etradecadienoylcarnitine	-0.053 (-0.105, 0)	0.049448	
2-aminobutyric acid	-0.037 (-0.073, 0)	0.049939	
icoseneoylcarnitine	-0.036 (-0.073, 0)	0.05045	
actic acid	-0.037 (-0.075, 0)	0.050511	
rimethylamine-N-oxide	-0.083 (-0.166, 0.001)	0.05328	
N –alpha acetyl-L-arginine	0.031 (-0.001, 0.062)	0.055828	
lydroxyproline	0.062 (-0.002, 0.125)	0.058796	
Cholesterol sulfate	-0.04 (-0.081, 0.002)	0.060322	
Pyroglutamic acid	0.021 (-0.002, 0.045)	0.070856	
V-2-furoylglycine	0.121 (-0.014, 0.257)	0.079555	
N-acetylglutamic acid	0.03 (-0.004, 0.065)	0.083373	
midazole-4-acetic acid			
	0.036 (-0.005, 0.078)	0.088661	

Table S6: Association of Dulaglutide with the 2-Year Change in Metabolite Levels

Valine	-0.016 (-0.035, 0.003)	0.093601
Oleoylcarnitine	-0.028 (-0.062, 0.005)	0.095826
Hexadecadienoylcarnitine	-0.04 (-0.087, 0.008)	0.101163
N-acetylcitrulline	0.031 (-0.007, 0.069)	0.109125
Homocitrulline	-0.047 (-0.105, 0.011)	0.114967
Arginine	0.022 (-0.006, 0.051)	0.125281
Octanoylcarnitine	-0.044 (-0.099, 0.012)	0.126389
Hydroxytetradecenoylcarnitine	-0.033 (-0.076, 0.01)	0.128735
Octenoylcarnitine	-0.041 (-0.096, 0.013)	0.135082
Tetradecenoylcarnitine	-0.041 (-0.094, 0.013)	0.135491
N-acetylthreonine	0.015 (-0.005, 0.034)	0.139269
Tryptophan	0.016 (-0.005, 0.038)	0.141038
Creatinine	0.015 (-0.005, 0.035)	0.142657
Acetylcarnitine	-0.021 (-0.05, 0.007)	0.144418
Serine	0.014 (-0.005, 0.033)	0.153896
Palmitoleoylcarnitine	-0.03 (-0.071, 0.011)	0.15624
Nicotinamide	-0.042 (-0.102, 0.018)	0.170963
N-acetylmethionine	0.015 (-0.007, 0.036)	0.17853
Octadecanoylcarnitine	-0.022 (-0.053, 0.01)	0.18037
Linoleoylcarnitine	-0.022 (-0.057, 0.012)	0.207461
Xanthurenic acid	0.013 (-0.008, 0.034)	0.22025
Decanoylcarnitine	-0.033 (-0.087, 0.021)	0.22987
1-methyladenosine	-0.018 (-0.048, 0.011)	0.230374
Decatrienoylcarnitine	-0.051 (-0.135, 0.033)	0.235701
Arachidoylcarnitine	-0.019 (-0.05, 0.013)	0.24208
Urea	-0.012 (-0.033, 0.009)	0.249459
Succinic acid	-0.018 (-0.048, 0.013)	0.250773
N-alpha-acetyllysine	-0.019 (-0.051, 0.013)	0.251681
Palmityolcarnitine	-0.016 (-0.044, 0.012)	0.27488
3-aminoisobutyric acid	0.028 (-0.024, 0.08)	0.289111
Heptanoylcarnitine	-0.03 (-0.085, 0.025)	0.290565
Methionine sulfoxide	0.018 (-0.015, 0.051)	0.291983
Betaine	0.013 (-0.012, 0.038)	0.299764
Myristoylcarnitine	-0.02 (-0.059, 0.018)	0.300856
N-acetylputrescine	-0.015 (-0.043, 0.013)	0.305131
3-methyl-2-oxovaleric acid	-0.014 (-0.04, 0.012)	0.30538
1-methylnicotinamide	-0.035 (-0.102, 0.032)	0.306477
N,N-dimethylglycine	0.026 (-0.025, 0.077)	0.309646
Butyrylcarnitine	0.02 (-0.019, 0.059)	0.314701
4-pyridoxic acid	0.048 (-0.05, 0.146)	0.334901
Phenylalanine	0.009 (-0.01, 0.027)	0.355904
2-hydroxyisocaproic acid	-0.015 (-0.047, 0.017)	0.360686
/		

C18:3 carnitine	-0.016 (-0.053, 0.02)	0.377092
Xanthine	0.024 (-0.03, 0.078)	0.380318
Mevalonic acid	0.033 (-0.04, 0.106)	0.382225
Kynurenic acid	-0.019 (-0.066, 0.029)	0.444633
4-oxoproline_pipecolic acid	-0.027 (-0.099, 0.044)	0.451506
N-epsilon-acetyllysine	0.007 (-0.012, 0.026)	0.461809
2,3-dihydroxybenzoic acid	0.04 (-0.075, 0.155)	0.491307
Dodecanoylcarnitine	-0.015 (-0.062, 0.032)	0.521192
Beta-alanine	-0.012 (-0.051, 0.027)	0.551536
Hydroxyoctenoylcarnitine	0.015 (-0.036, 0.066)	0.564465
Arachidonoylcarnitine	-0.012 (-0.052, 0.028)	0.566211
N-acetylaspartic acid	0.005 (-0.013, 0.024)	0.567771
Isoleucine	-0.007 (-0.03, 0.017)	0.574595
Malic acid	-0.012 (-0.056, 0.031)	0.579001
Glutaric acid	0.017 (-0.045, 0.078)	0.60072
Proline	0.007 (-0.019, 0.033)	0.602498
Phenylpyruvic acid	0.009 (-0.025, 0.043)	0.604217
Kynurenine	0.007 (-0.019, 0.033)	0.608161
Allantoin	0.007 (-0.021, 0.035)	0.610006
Decadienoylcarnitine	-0.014 (-0.067, 0.04)	0.619767
2,3-pyridinedicarboxylic acid	-0.012 (-0.06, 0.037)	0.642837
Taurine	0.01 (-0.033, 0.053)	0.661469
N-acetylserine	0.004 (-0.015, 0.022)	0.699988
Lysine	0.006 (-0.025, 0.037)	0.717826
Sarcosine	0.01 (-0.043, 0.063)	0.717886
S-adenosylhomocysteine	-0.007 (-0.048, 0.033)	0.729121
Glutamic acid	0.006 (-0.03, 0.042)	0.734843
N-acetyltryptophan	-0.005 (-0.04, 0.029)	0.758412
N-acetylalanine	0.002 (-0.013, 0.018)	0.772915
2-aminoadipic acid	-0.005 (-0.043, 0.032)	0.78199
Pantothenic acid	-0.005 (-0.045, 0.035)	0.805055
Citric acid	-0.004 (-0.033, 0.026)	0.816941
Uric acid	-0.003 (-0.027, 0.021)	0.819102
Isovalerylcarnitine	-0.006 (-0.061, 0.049)	0.826214
Hypoxanthine	0.005 (-0.049, 0.06)	0.84559
Trans aconitic acid	0.003 (-0.03, 0.036)	0.85435
C6:2 carnitine	0.009 (-0.099, 0.117)	0.865483
Riboflavin	0.003 (-0.037, 0.044)	0.873936
Propionylcarnitine	-0.003 (-0.038, 0.032)	0.879086
Aspartic acid	0.003 (-0.041, 0.047)	0.894736
Symmetric dimethylarginine	0.001 (-0.022, 0.025)	0.902373
Inosine	-0.007 (-0.132, 0.117)	0.906531
-	()	

Alanine	0.001 (-0.02, 0.023)	0.922676
1-methylhistidine	-0.002 (-0.041, 0.038)	0.932877
S-methylcysteine sulfoxide	-0.003 (-0.069, 0.063)	0.934997
Isocitric acid	-0.002 (-0.06, 0.055)	0.936644
Alpha-ketoglutaric acid	0.002 (-0.047, 0.051)	0.943576
3-methylhistidine	0.005 (-0.128, 0.137)	0.945936
Histidine	0.001 (-0.024, 0.026)	0.951888
Guanosine	0.004 (-0.151, 0.16)	0.954978
Ethanolamine	0 (-0.024, 0.023)	0.969259
S-methylcysteine	-0.001 (-0.057, 0.054)	0.969628
N-acetylornithine	0 (-0.056, 0.057)	0.990867

The effect of dulaglutide on the 2-year difference of the natural logarithm (In) levels of each metabolite calculated as In (2-year/baseline) adjusted for In (baseline biomarker level), age, sex, white identification, systolic blood pressure, previous cardiovascular disease, current smoking, body mass index, HbA1c, eGFR, LDL cholesterol, and albuminuria is shown. The biomarkers are sorted from the lowest to highest P values for the beta coefficient; only the subset with a P value <0.05 is shown). Negative values denote a greater fall in level from baseline to 2 years with dulaglutide versus placebo. *P values that are significant at a level of 0.05/135 = 0.00037. ¹CMPF - carboxy-4-methyl-5-propyl-2-furanpropanoic acid